# China NMPA Drug Inspection - Hubei Danao Pharmaceutical Co., Ltd. - Anluotong tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-danao-pharmaceutical-co-ltd/95d93c3b-6204-4b8f-9661-ca266a860986/
Source feed: China

> China NMPA drug inspection for Hubei Danao Pharmaceutical Co., Ltd. published November 24, 2017. Drug: Anluotong tablets. The Henan Provincial Food and Drug Administration announced on November 24, 2017, findings from drug quality inspections

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Henan Provincial Food and Drug Administration Regarding 3 Batches of Substandard Drugs Found in Spot Checks
- Company Name: Hubei Danao Pharmaceutical Co., Ltd.
- Publication Date: 2017-11-24
- Drug Name: Anluotong tablets
- Inspection Finding: Properties are not up to standard
- Action Taken: Risk control measures such as sealing, seizing, and suspending sales; legal action against the units that source the inspected goods.
- Summary: The Henan Provincial Food and Drug Administration announced on November 24, 2017, findings from drug quality inspections identifying three companies for producing substandard pharmaceutical products. Huixian Baiquan Traditional Chinese Medicine Pieces Co., Ltd.'s Epimedium (batch 161201) was found to have substandard content. Shandong Zhencheng Zhiyuan Traditional Chinese Medicine Pieces Co., Ltd. produced Coltsfoot Flower (batch 16061901) with a substandard appearance. Hubei Meibao Pharmaceutical Co., Ltd.'s Anluotong Tablets (batch 160506) also exhibited a substandard appearance. These issues were detected through testing by various provincial and municipal drug inspection institutes. Operating under the regulatory framework of the Henan Provincial Food and Drug Administration, which is part of the National Medical Products Administration (NMPA) system in China, the authority mandated immediate risk control measures. Required actions include the sealing, seizing, and suspending sales of the affected drugs. Additionally, regulatory departments were instructed to investigate and impose legal penalties on the responsible companies to ensure compliance with quality standards and public safety.

Company: https://www.globalkeysolutions.net/companies/hubei-danao-pharmaceutical-co-ltd/25d0977f-931a-4b67-9082-7bfed3e082bb/